Amendment to Executive Employment Agreement between Qualigen Therapeutics, Inc. and Dr. Tariq Arshad (January 13, 2023)
Qualigen Therapeutics, Inc. and Dr. Tariq Arshad have agreed to temporarily reduce Dr. Arshad's annual base salary by 20%, lowering it to $320,000, effective January 16, 2023. This amendment is part of company-wide cost-cutting measures approved by the board of directors. The agreement reflects the company's appreciation for Dr. Arshad's continued service and aims to help position the company for future success.
Exhibit 10.33
Amendment to Executive Employment Agreement with Tariq Arshad, dated January 13, 2023
January 13, 2023
Dear Dr. Arshad:
As you may know, on January 13, 2023, the board of directors of Qualigen Therapeutics, Inc. (the “Company”), as part of certain cost-cutting measures across the Company, approved a temporary 20% reduction to the base salaries of all executive officers of the Company.
To that end, effective as of January 16, 2023, your annual base salary will be reduced to $320,000.
We truly appreciate your loyalty, hard work and commitment to the Company. With your help and cooperation, I am confident that we will emerge stronger and hopeful the changes will allow us to effectively position the Company for future success.
Sincerely,
Michael Poirier
Chairman and CEO of Qualigen Therapeutics, Inc.
